Abstract Details

Title The Impact of Offering Monthly and Quarterly Dosing Options for a New Class of Migraine Preventive Therapy on Likelihood of Acceptance and Adherence in Adults With Migraine

Topic Headache

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 13-013

Objective This study sought to understand the impact of having both monthly and quarterly dosing options on acceptance of, and adherence to, a new class of migraine preventive therapy among adults with migraine.

Background Migraine affects approximately 39 million people in the US. A new class of migraine preventive therapy launching in 2018-2019 will provide physicians and patients with an alternate approach to preventive treatment.

Design/Methods In this double-blind, observational study, 417 US adults with migraine completed a 20-minute, self-administered online survey. Respondents included 228 moderate-frequency episodic (5–9 headache days/month), 103 high-frequency episodic (10–14 headache days/month), and 86 chronic migraine patients (≥15 headache days/month). Respondents were exposed to three scenarios: only monthly dosing of the new class of migraine preventive therapy is available; only quarterly dosing is available; and both monthly and quarterly dosing are available. In each scenario, respondents were asked their likelihood to fill the prescription and take it consistently over one year, measured on a 7-point scale where 1=“not at all likely” and 7=“extremely likely” (6 or 7 were classified “likely”).

Results A similar proportion of respondents preferred monthly (35.3%) and quarterly (39.8%) dosing regimens (24.9% had no preference). Among those who preferred monthly dosing (n=147), a greater proportion indicated they were likely to fill the prescription and remain adherent when only monthly is available compared to when only quarterly is (77% vs. 56% P<0.05 and 80% vs. 57% P<0.05). Among those who preferred quarterly dosing (n=166), a greater proportion indicated they were likely to fill and remain adherent when only quarterly is available compared to when only monthly is (63% vs. 55% P<0.05 and 62% vs. 54% P<0.05).

Conclusions Adults with migraine are more likely to accept and adhere to the new class of preventive therapy when presented with their preferred dosing regimen.

Authors/Disclosures
Robert Cowan, MD, FAAN (Stanford Neurosciences Health Center) PRESENTER	Dr. Cowan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Cowan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Cowan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for lundbeck. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biohavenn. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbviie. Dr. Cowan has stock in Percept. Dr. Cowan has received intellectual property interests from a discovery or technology relating to health care. Dr. Cowan has received intellectual property interests from a discovery or technology relating to health care. Dr. Cowan has received publishing royalties from a publication relating to health care.
	No disclosure on file
	No disclosure on file
Ravi Iyer	No disclosure on file

��ɫ��

��ɫ��